Investigating how Spautin-1 can degrade a key protein in myeloma treatment
Mechanism of Action of Spautin-1, A Novel Degrader of IKZF1
This study is looking at a new compound called Spautin-1 to see how well it can help treat multiple myeloma by breaking down a protein that makes it hard for current treatments to work, with the hope of creating better options for patients who aren't responding to existing therapies.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10866353 on NIH RePORTER |
What this research studies
This research focuses on understanding how Spautin-1, a novel compound, can effectively degrade the IKZF1 protein, which is crucial in the treatment of multiple myeloma. The study involves identifying the specific mechanisms through which Spautin-1 operates and determining its effectiveness in overcoming resistance to existing immunomodulatory drugs. By conducting a series of genetic and biochemical experiments, the researchers aim to develop more potent derivatives of Spautin-1 that can be used in clinical settings. Patients may benefit from new treatment options that target myeloma cells resistant to current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with multiple myeloma, particularly those who have developed resistance to immunomodulatory drugs.
Not a fit: Patients with other types of cancer or those who do not have multiple myeloma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with myeloma who are resistant to current therapies.
How similar studies have performed: While the approach of using small molecule degraders is gaining traction, the specific application of Spautin-1 in this context is novel and has not been extensively tested.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Koduri, Vidyasagar — Brigham and Women's Hospital
- Study coordinator: Koduri, Vidyasagar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.